NEW YORK, Nov. 20, 2003 (PRIMEZONE) -- Advanced Plant Pharmaceuticals, Inc. (OTCBB:APPI), announced that the company's exclusive marketing partner for Lo-Chol, Nutralife Pharmaceuticals Corp. has signed an exclusive distribution agreement with the second-largest direct response marketing company in Greece with an initial order of 5,000 bottles.
In order to maintain it's exclusive license in Greece, the distributor is required to make subsequent purchases of Lo-Chol, in the aggregate amount of 50,000 bottles, over the next twelve months, although it is not obligated to make such subsequent purchases.
David Lieberman, CEO of Advanced Plant Pharmaceuticals, said, "This announcement of Telestar joining the Lo-Chol worldwide marketing network marks the third European distributor covering four nations to sign on with our marketing partner, Nutralife Pharmaceuticals. We believe that we are gaining some momentum in expanding our marketing reach globally and look forward to additional agreements to be consummated going forward."
Advanced Plant Pharmaceuticals, Inc. (APPI) focuses on the research and development of plant-based dietary supplements. The Company has a patent pending process that utilizes whole plants to manufacture all natural dietary supplements. APPI uses this process to manufacture products, which the company plans to distribute worldwide through various sales distribution contracts or majority-owned spin-off companies. Current products include Sinusol (homeopathic allergy and nasal spray), Garlic, ACA (immune system booster) and the patented Lo-Chol. Corporate website: http://www.appi.cc
NutraLife Pharmaceuticals, Corp. is a newly established direct response and marketing firm focused on the development and design of marketing programs for a range of commercial products, including production, media buying, fulfillment, direct response, telemarketing, customer service and retail integration and distribution.
FORWARD LOOKING STATEMENTS:
This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.